Hepatitis C drug, Vosevi, receives FDA nod
by Press Release from Outbreak News Today on (#2WT16)
The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs - sofosbuvir and velpatasvir - and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been ["]
The post Hepatitis C drug, Vosevi, receives FDA nod appeared first on Outbreak News Today.